Breaking News

Monday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
TDOC Teladoc $65.99 3.57 (5.72%) 08:46 10/15/18 10/15 08:46 10/15/18 08:46 Recommendations	Teladoc analyst commentary at Craig-Hallum » Teladoc price target… Teladoc price target raised to $80 from $70 at Craig-Hallum. Craig-Hallum analyst Matt Hewitt raised his price target for Teladoc to $80 from $70, while reiterating a Buy rating on the shares. After rallying nicely following a very positive analyst day, the stock has fallen back about 26% creating a buying opportunity, he contends. The analyst notes that utilizing a combination of both organic and inorganic activity, Teladoc has been able to post rapid revenue growth and maintain a dominant lead in the telehealth landscape. Hewitt believes that as the clear scale advantage Teladoc has established expands internationally via its acquisition of Advance Medical in June, the company can leverage existing relationships to cross-sell offerings. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Nov
TDOC Teladoc $65.99 3.57 (5.72%) 07:25 10/15/18 10/15 07:25 10/15/18 07:25 Recommendations	Teladoc analyst commentary at Jefferies » Teladoc added to… Teladoc added to Franchise Picks List at Jefferies. Jefferies analyst Sean Dodge added Teladoc to his firm's Franchise Picks List saying the recent 26% pullback in the shares creates an attractive entry point into "one of the most disruptive companies in the space." The deal with CVS, which is on track to deliver 200,000-plus paid visits in 2019, improve visibility on the company's 25%-plus organic revenue growth, Dodge tells investors in a research note. Teladoc's model is "one of the best aligned with all the winds of change blowing" in healthcare, the analyst contends. He keeps a Buy rating on the shares with a $95 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Nov

Over a week ago
TDOC Teladoc $70.96 -4.88 (-6.43%) 16:32 10/08/18 10/08 16:32 10/08/18 16:32 Initiation	Teladoc initiated at Credit Suisse » Teladoc initiated with a… Teladoc initiated with a Neutral at Credit Suisse. Credit Suisse analyst Jailendra Singh initiated Teladoc with a Neutral rating and a price target of $80, saying the company's revenue is on track for a 29% organic growth rate and 75% overall from 2014-2018 driven by growth in membership, visits, and revenue per member. The analyst is positive on the company's position in the "fast growing Business-to-Business-to-Consumer telehealth industry" amid a shortage of physician and rising costs but sees the valuation on the shares as fair. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Nov
TSLA Tesla $264.29 -43.17 (-14.04%) , FB Facebook $164.44 -4.44 (-2.63%) … 19:26 09/30/18 09/30 19:26 09/30/18 19:26 Hot Stocks	Fly Intel: Top five weekend stock stories » Catch up on the… Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The Securities and Exchange Commission announced that Elon Musk, CEO and Chairman of Tesla (TSLA), has agreed to settle the securities fraud charge brought by the SEC against him last week. The SEC also charged Tesla with failing to have required disclosure controls and procedures relating to Musk's tweets, a charge that Tesla has agreed to settle. According to the settlements, Musk will step down as Tesla's Chairman and be replaced by an independent Chairman, with Musk ineligible to be re-elected Chairman for three years. Meanwhile, Tesla will appoint a total of two new independent directors to its board and will establish a new committee of independent directors and put in place additional controls and procedures to oversee Musk's communications. Further, Musk and Tesla will each pay a separate $20M penalty. 2. A European Union privacy watchdog could fine Facebook (FB) as much as $1.63B for a data breach in which hackers compromised the accounts of more than 50M users, if regulators find the company violated the bloc's strict new privacy law, according to The Wall Street Journal. 3. Potential electoral results could favor the outlook for policies beneficial to a wide range of hospital, pharmaceutical, and other health-care-related companies, Lauren Rublin wrote in this week's edition of Barron's. Policy experts favor Centene (CNC), WellCare Health (WCG), Molina Healthcare (MOH), HCA Healthcare (HCA), Tenet (THC), Encompass Health (EHC), Becton Dickinson (BDX), Cerner (CERN), Dentsply Sirona (XRAY) and Teladoc Health (TDOC) as beneficiaries of Medicaid expansion under the Affordable Care Act, the reported noted, adding that is especially likely if Democrats win more state elections. 4. Comcast (CMCSA) subsidiary Universal's "Night School" debuted to $28M from 3,010 theaters, taking the number one spot of the domestic box office. Overseas, Kevin Hart and Tiffany Haddish's raucous comedy launched to $5.5M from its first 19 markets for $33.5M globally. The movie earned an A- CinemaScore and sports 30% Rotten Tomatoes score. 5. Hasbro (HAS), Royal Dutch Shell (RDS.B, RDS.A), Sanofi (SNY), and IBM (IBM) saw positive mentions in Barron's, while Trupanion's (TRUP) and Tesla were mentioned cautiously. TSLA Tesla $264.29 -43.17 (-14.04%) FB Facebook $164.44 -4.44 (-2.63%) CNC Centene $144.81 1.61 (1.12%) WCG WellCare $320.50 -0.22 (-0.07%) MOH Molina Healthcare $148.73 1.01 (0.68%) HCA HCA Healthcare $139.09 0.75 (0.54%) THC Tenet $28.45 0.1 (0.35%) EHC Encompass Health $78.01 1.33 (1.73%) BDX Becton Dickinson $260.90 1.04 (0.40%) CERN Cerner $64.42 0.21 (0.33%) XRAY Dentsply Sirona $37.74 -0.22 (-0.58%) TDOC Teladoc $86.35 3.85 (4.67%) CMCSA Comcast $35.42 0.19 (0.54%) CMCSK Comcast $0.00 (0.00%) HAS Hasbro $105.12 -0.88 (-0.83%) RDS.A Royal Dutch Shell $68.13 -0.61 (-0.89%) RDS.B Royal Dutch Shell $70.93 -0.37 (-0.52%) SNY Sanofi $44.67 -0.17 (-0.38%) IBM IBM $151.20 -0.3 (-0.20%) TRUP Trupanion $35.73 0.81 (2.32%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Oct 03 Oct 09 Oct 11 Oct 20 Oct 21 Oct 22 Oct 22 Oct 23 Oct 28 Oct 28 Oct 29 Oct 29 Oct 30 Oct 06 Nov 07 Nov 13 Nov 11 Dec 14 Dec 28 Jan 03 Mar 22 Mar 28 Apr
CNC Centene $144.81 1.61 (1.12%) , WCG WellCare $320.50 -0.22 (-0.07%) … 11:52 09/29/18 09/29 11:52 09/29/18 11:52 Periodicals	Midterms could boost some healthcare stocks, Barron's says » Potential electoral… Potential electoral results could favor the outlook for policies beneficial to a wide range of hospital, pharmaceutical, and other healthcare-related companies, Lauren Rublin writes in this week's edition of Barron's. Policy experts favor Centene (CNC), WellCare Health (WCG), Molina Healthcare (MOH), HCA Healthcare (HCA), Tenet (THC), Encompass Health (EHC), Becton Dickinson (BDX), Cerner (CERN), Dentsply Sirona (XRAY) and Teladoc Health (TDOC) as beneficiaries of Medicaid expansion under the Affordable Care Act, the reported noted, adding that is especially likely if Democrats win more state elections. Reference Link CNC Centene $144.81 1.61 (1.12%) WCG WellCare $320.50 -0.22 (-0.07%) MOH Molina Healthcare $148.73 1.01 (0.68%) HCA HCA Healthcare $139.09 0.75 (0.54%) THC Tenet $28.45 0.1 (0.35%) EHC Encompass Health $78.01 1.33 (1.73%) BDX Becton Dickinson $260.90 1.04 (0.40%) CERN Cerner $64.42 0.21 (0.33%) XRAY Dentsply Sirona $37.74 -0.22 (-0.58%) TDOC Teladoc $86.35 3.85 (4.67%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Oct 11 Oct 23 Oct 30 Oct 06 Nov 11 Dec 14 Dec

TDOC Teladoc $82.50 4.05 (5.16%) 08:11 09/28/18 09/28 08:11 09/28/18 08:11 Recommendations	Teladoc analyst commentary at Cantor Fitzgerald » Teladoc price target… Teladoc price target raised to $83 from $52 at Cantor Fitzgerald. Cantor Fitzgerald analyst Steven Halper raised his price target for Teladoc to $83 saying the company at its investor meeting provided a bullish overview of its long-term growth potential. The analyst, however, reiterates a Neutral rating on the shares. He believes the stock at current valuation levels reflects his revised long-term growth assumptions. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $82.50 4.05 (5.16%) 07:51 09/28/18 09/28 07:51 09/28/18 07:51 Recommendations	Teladoc analyst commentary at Citi » Teladoc price target… Teladoc price target raised to $95 from $88 at Citi. Citi analyst Stephanie Demko raised her price target for Teladoc to $95 after the company held its second annual investor day yesterday. Management's tone was positive on the macro environment, new wins and momentum as the business gains scale, Demko tells investors in a research note. She left the meeting "incrementally more positive" on the company's growth sustainability through 2020 and beyond. The analyst reiterates a Buy rating on Teladoc. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $82.50 4.05 (5.16%) 07:42 09/28/18 09/28 07:42 09/28/18 07:42 Recommendations	Teladoc analyst commentary at Canaccord » Teladoc price target… Teladoc price target raised to $94 from $86 at Canaccord. Canaccord analyst Richard Close raised his price target on Teladoc to $94 from $86 following its "impressive" investor day. The analyst noted the company raised its guidance and shed some light on the international opportunity. He believes the company has strong sustainable momentum with global opportunities and is just beginning to scratch the surface. Close reiterated his Buy rating on Teladoc shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TDOC Teladoc $82.50 4.05 (5.16%) , CNC Centene $143.20 1.67 (1.18%) … 07:16 09/28/18 09/28 07:16 09/28/18 07:16 Recommendations	Teladoc, Centene, Exxon Mobil analyst commentary at Oppenheimer » Teladoc price target… Teladoc price target raised to $89 from $68 at Oppenheimer. Oppenheimer analyst Mohan Naidu reiterated an Outperform rating on Teledoc and raised his price target to $89 from $68 following the company's analyst day, which highlighted its new deal flow, including relationships with Centene (CNC) and Exxon (XOM), and a very strong pipeline. The recent CMS telehealth proposal makes Medicare a 2020 tailwind, Naidu tells investors in a research note, and says he has gained confidence that Teladoc's competitive barriers include its broad platform and its network of physicians that quickly matches supply and demand. TDOC Teladoc $82.50 4.05 (5.16%) CNC Centene $143.20 1.67 (1.18%) XOM Exxon Mobil $85.78 -0.005 (-0.01%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Sep 11 Oct 23 Oct 14 Dec
TDOC Teladoc $82.50 4.05 (5.16%) 06:54 09/28/18 09/28 06:54 09/28/18 06:54 Recommendations	Teladoc analyst commentary at KeyBanc » Teladoc price target… Teladoc price target raised to $94 from $90 at KeyBanc. KeyBanc analyst Donald Hooker reiterated an Overweight rating on Teledoc (TDOC) and raised his price target to $94 from $90 after attending the company's investor day. The company disclosed a new relationship with Centene (CNC) at the event, which has the potential to expand across Centene's broader 12M+ membership over time, Hooker tells investors in a research note. Teledoc is is generating more scale than he had anticipated, and he now expects positive free cash flow in 2019. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

On The Fly

News and insights, exclusive to thefly.com

12:41	Fly Intel: Wall Street's top stories at midday»
12:07	Shopify drops almost 8% following report Trump ending China shipping treaty»
10:46	Homebuilders continue tumble as Credit Suisse downgrades several in space»
10:37	Street Fight: KeyBanc cuts Netflix rating as peers say 'growth story is back'»
10:28	On The Fly: Top five analyst initiations»

View all On The Fly Stories »

Upcoming
Events (10)

BKD ...	RBC Capital Company Meetings at NIC Fall Conference 2018
BKD ...	NIC Fall Conference 2018
	Advertising and Promotion for Medical Products Conference
GLMD ...	Roth Battle of the NASH Thrones Investor Conference
	Adobe MAX
	Pipestone Focused Mini-Conference
PFE ...	Biosimilars in China
ARQL	ASHG Conference 2018
	Teradata Analytics Universe
	NBAA Business Aviation Convention & Exhibition (NBAA-BACE)

View all of today’s events »

Today’s
Syndicate (2)

SIBN	IPO
CVU	Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial